Market Overview

Argus Upgrades Quest Diagnostics, Cites Several Key Catalysts

Share:
Argus Upgrades Quest Diagnostics, Cites Several Key Catalysts
Related DGX
The Daily Biotech Pulse: Tracon Aces Early-Stage Trials, Boston Scientific To Buy Out Millipede
10 Biggest Price Target Changes For Friday
Goldman bullish on Insmed in premarket analyst action (Seeking Alpha)

Quest Diagnostics Inc (NYSE: DGX) has a number of bullish catalysts on the horizon, enough for one Wall Street analyst to upgrade the stock.

The Analyst

Argus analyst Jasper Hellweg upgraded Quest from Hold to Buy and set a $116 price target for the stock.

The Thesis

Quest simply has too strong of a cash position to ignore. Hellweg said the company has strong cash flow, is conscious of limiting costs and has been aggressive about capital return. In fact, the company recently issued an 11 percent dividend hike, its first since Q1 of 2016.

In 2017 Quest reported $1.18 billion in cash from operations, a nearly 10 percent increase from the year before.

In coming quarters, Hellweg said Quest will also begin to benefit from both a lower tax rate and its handful of recent acquisitions.

In addition to the upgrade, Argus raised its 2018 EPS forecast from $5.79 to $6.59 and set a 2018 EPS target of $6.91. Hellweg said investors should keep a close eye on changed to Medicaid payments for lab fees in 2019, which could potentially limit earnings growth. However, Argus still expects Quest to be able to deliver long-term earnings growth of around 7 percent.

“Although Quest may face pressure from lower Medicaid payment rates for clinical laboratory tests, we expect a greater impact on smaller peers, which may lead to additional acquisition opportunities,” Hellweg said.

Price Action

Quest opened Wednesday’s session down 0.6 percent and is now up 5.5 percent year-to-date.

Related Links:

Height Securities: The Clock Is Ticking For Big Pharma As Congressional Spending Cuts Loom

Pot Stocks, ETFs And Top News From The Cannabis Industry This Week

Latest Ratings for DGX

DateFirmActionFromTo
Jan 2019UBSInitiates Coverage OnNeutral
Jan 2019Bank of AmericaDowngradesNeutralUnderperform
Nov 2018BarclaysMaintainsOverweightOverweight

View More Analyst Ratings for DGX
View the Latest Analyst Ratings

Posted-In: Argus Jasper HellwegAnalyst Color Upgrades Price Target Analyst Ratings Best of Benzinga

 

Related Articles (DGX)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
MDRXKeyBancUpgrades0.0
ANETNomuraUpgrades260.0
CNPRBC CapitalUpgrades34.0
FISVOppenheimerUpgrades88.0
FNDUBSUpgrades37.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

William Blair Raises Ciena Estimates After Q1 Report, Says Company Has 'Market-Leading' Product Portfolio

Largest Stock Holdings Of Andreas Halvorsen's New-Look Viking Global